Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells

As an approach to the rational design of combination chemotherapy involving the anti-cancer DNA topoisomerase II poison etoposide (VP-16), we have studied the dynamic changes occurring in small-cell lung cancer (SCLC) cell populations during protracted VP-16 exposure. Cytometric methods were used to...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 1994-11, Vol.70 (5), p.914-921
Hauptverfasser:	Smith, PJ, Souès, S, Gottlieb, T, Falk, SJ, Watson, JV, Osborne, RJ, Bleehen, NM
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedical and Life Sciences Biomedicine Bromodeoxyuridine Cancer Research Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - enzymology Carcinoma, Small Cell - pathology Cell Cycle - drug effects DNA Damage DNA Topoisomerases, Type II - drug effects DNA Topoisomerases, Type II - metabolism Drug Resistance Epidemiology Etoposide - pharmacology experimental-oncology Flow Cytometry G1 Phase - drug effects Genes, p53 Humans Kinetics Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - pathology Molecular Medicine Mutation Oncology S Phase - drug effects Tumor Cells, Cultured
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!